Skip to content

Study · Randomized controlled trial · n = 71 · 2025

2 results

Efficacy of Linaclotide in Functional Dyspepsia and Constipation-Predominant Irritable Bowel Syndrome Overlap: A Randomized Trial.

Cheng L, Wang Q, Wu B, Yan X, Xu P, Qiu H, Chen S

Journal of gastroenterology and hepatology13 Mar 2025Cited by 1 (Europe PMC)

PMID40079184 (opens in a new tab)DOI10.1111/jgh.16925 (opens in a new tab)PepBankPUB-40079184
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with functional dyspepsia and IBS-C overlap, relief occurred in 87.2% with linaclotide versus 54.2% with lactulose (p = 0.002).

    In plain wordsPatients reported more gastrointestinal symptom relief with linaclotide than with lactulose.

    Peptide
    Linaclotide
    Outcome
    IncreasePartial or complete gastrointestinal symptom relief
    Study

    n = 71

    Comparator
    Lactulose 20 mL daily
    Analysis
    Primary
    Outcome group
    Gastrointestinal Symptoms · Gastrointestinal
    Studied dose
    290 μg daily · 4 weeksAs given in this study (human).

    Measurements

    Relief
    87.2%
    linaclotide
    Relief
    54.2%
    lactulose

    Source sentences

    Summary
    A higher proportion of patients receiving linaclotide reported partial or complete relief of gastrointestinal symptoms compared with patients receiving lactulose (87.2% vs. 54.2%, p = 0.002).
    1 context sentence
    Summary · context
    Seventy-eight patient were randomized (2:1) to receive linaclotide 290 μg or lactulose 20 mL daily for 4 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with functional dyspepsia and IBS-C overlap, linaclotide improved fullness/early satiety, bloating, stool frequency, consistency, straining, complete evacuation, and lower abdominal discomfort more than lactulose (p < 0.05).

    In plain wordsDyspeptic and bowel symptoms improved more with linaclotide than with lactulose.

    Peptide
    Linaclotide
    Outcome
    Direction not reportedDyspeptic and bowel symptoms
    Study

    n = 71

    Comparator
    Lactulose 20 mL daily
    Analysis
    Secondary
    Outcome group
    Gastrointestinal Symptoms · Gastrointestinal
    Studied dose
    290 μg daily · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Dyspeptic symptoms (postprandial fullness/early satiety and bloating) and bowel symptoms (stool frequency, consistency, straining, sensation of complete evacuation, and lower abdominal discomfort) showed greater improvement in linaclotide-treated patients than in lactulose group (p < 0.05).
    1 context sentence
    Summary · context
    Seventy-eight patient were randomized (2:1) to receive linaclotide 290 μg or lactulose 20 mL daily for 4 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT05134584

Efficacy of Linaclotide in Patients With Overlapping Functional Gastrointestinal Disorders

RenJi Hospitaln = 781 Jan 2021 to est. Feb 2022

Functional Dyspepsia · Constipation-predominant Irritable Bowel Syndrome

Trial pageClinicalTrials.govUpdated 13 Dec 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.